Tango Therapeutics, Inc.
Tango Therapeutics, Inc. is a U.S.-based precision oncology company focused on discovering and developing targeted cancer therapies for genetically defined patient populations. Its pipeline centers on small-molecule drug candidates designed to selectively attack cancer cells with specific genetic alterations while sparing normal cells.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDrug candidates in human clinical development for genetically defined cancers.
Revenue recognized from partnered research and licensing arrangements.
Internal discovery capabilities used to identify disease-relevant oncology targets.
Products
Reported · share of revenue- Collaboration Revenue71.2 %
- License Revenue28.8 %
Source: 10-K FY2024, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Tango Therapeutics does not sell commercial products today; its economic counterparties are pharmaceutical collaborators, research partners, and future oncology patients through regulated drug development. In the current model, revenue is primarily tied to collaboration agreements, while the eventual commercial customer base would be hospitals, oncologists, and payors if product candidates are approved.
Buy access to discovery, research, and licensing rights in oncology programs.
Hospitals, cancer centers, and oncologists that would use approved therapies.
Assess clinical value and coverage for any approved cancer medicines.
Support target validation, biomarker work, and early-stage development.
Strategy
Tango Therapeutics is focused on advancing genetically targeted oncology programs through clinical proof-of-concept and biomarker-driven development. Its strategy relies on selecting cancer vulnerabilities such as MTAP deletion and building differentiated small molecules that can be paired with combination regimens or used in CNS settings.
Clinical validation is the main path to value creation for a pre-commercial oncology company.
Targeting MTAP-deleted tumors can improve selectivity and clinical relevance.
Combination regimens and brain-penetrant assets broaden the addressable oncology market.
The company depends on collaboration revenue and capital markets to finance development.
Geography
The company is headquartered in the United States and conducts its core research and development activities from Boston, Massachusetts. Its operational footprint also depends on third-party manufacturing and clinical supply chains, including a supplier located in China, which creates geographic exposure in both development execution and supply continuity.
Risks
The company faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory approval risk, and the need for substantial external funding before any product sales. It also has meaningful supply-chain concentration, including single-source or limited-source API and drug-product manufacturing, and its oncology programs face intense competition from other PRMT5 and precision oncology developers.
- Clinical development failureImpact: HighLikelihood: High
Pipeline value depends on demonstrating safety and efficacy in human trials.
Exposure - Capital dependenceImpact: HighLikelihood: High
The company must fund long-duration R&D before product revenue exists.
Exposure - Manufacturing and supply concentrationImpact: HighLikelihood: Medium
API and drug product rely on a small number of third-party suppliers.
Exposure: Clinical trial supply and future commercial supply
- China-related supply chain exposureImpact: MediumLikelihood: Medium
One CDMO is located in China, creating geopolitical and logistics risk.
Exposure: API and drug product sourcing
- Competitive pressure in oncologyImpact: MediumLikelihood: Medium
Other companies are developing PRMT5 and related precision oncology programs.
Exposure: PRMT5 inhibitor market and broader oncology pipeline
- Pricing and reimbursement riskImpact: MediumLikelihood: Low
Future approved therapies may face coverage limits and pricing pressure.
Exposure: U.S. and ex-U.S. commercialization
Accounting
Judgemental itemsGilead-style agreements may include upfront, extension, milestone, and royalty elements.
Impact: Affects timing and volatility of reported revenue
Upfront collaboration consideration may be recognized over future periods.
Impact: Can materially shift revenue between quarters and years
Future payments depend on development, regulatory, and commercial events.
Impact: Affects future expense recognition and cash outflows
Office and laboratory leases create operating lease liabilities and ROU assets.
Impact: Affects balance sheet leverage and operating expense presentation
Third-party CRO and CDMO services require estimates for work performed but not billed.
Impact: Can affect R&D expense timing and comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
Sangamo Therapeutics, Inc
SGMOQ · Biological Products, (No Diagnostic Substances)
Sangamo Therapeutics is a U.S.-based genomic medicine company focused on developing therapies and enabling technologies built around zinc finger biology,…
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026